Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 9/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29563266 | 1.00 | RYR2 (0.48) | RYR2KCNH2SLC6A2SLC6A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL29563444 | 0.99 | RYR2 (0.47) | RYR2KCNH2SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL26942225 | 0.89 | RYR2 (0.56) | RYR2KCNH2EPHX2 | |
| SCHEMBL29563519 | 0.83 | RYR2 (0.48) | RYR2KCNH2SLC6A2SLC6A4HTR2A | |
| SCHEMBL24460348 | 0.83 | RYR2 (0.48) | RYR2KCNH2SLC6A2SLC6A4HTR2A | |
| Hydrochloric Acid SCHEMBL29564238 | 0.82 | RYR2 (0.47) | RYR2KCNH2SLC6A2SLC6A4HTR2A | |
| SCHEMBL24460459 | 0.82 | RYR2 (0.51) | RYR2KCNH2CA2CHKA | |
| SCHEMBL29563568 | 0.82 | RYR2 (0.51) | RYR2KCNH2CA2CHKA | |
| Hydrochloric Acid SCHEMBL29563975 | 0.81 | RYR2 (0.50) | RYR2KCNH2CA2CHKA | |
| SCHEMBL24460447 | 0.79 | RYR2 (0.51) | RYR2KCNH2CA2CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399324-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RYCARMA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399324-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RYCARMA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2022108945-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | ARMGO PHARMA, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399324-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RYR2, RYR1, ATP2A1 | RYR2 1/4885KCNH2 605/4885SLC6A2 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.